Add to ORKGYC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinom
Introduction:Targeting signal transducer and activator of transcription 3 (STAT3), a transcription f...
Sorafenib inhibits intracellular signaling pathways addition to inhibiting AKT and receptor tyrosine...
none4noHepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldw...
Background: Traditional systemic chemotherapy does not provide survival benefits in patients with he...
The present study investigated the effect of YC-1, a novel anti-cancer agent, on the chemo-sensitivi...
Background& Aims: Recently, we reported that sorafenib sensitizes hepatocellular carcinoma (HCC) cel...
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer with incidence increasing w...
Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after i...
YC-1 has recently been demonstrated to have potent anti-invasion and anti-metastatic activity in sev...
PURPOSE: Recombinant tumor necrosis factor-related apoptosis -inducing ligand (TRAIL) is a promising...
Hypoxia-inducible factor-1alpha (HIF-1alpha) seems central to tumor growth and progression because i...
BACKGROUND AND PURPOSE YC-1 exhibits potent anticancer activity via numerous actions in many cancer...
The role of a YAP-IGF-1R signaling loop in HCC resistance to sorafenib remains unknown. Method: Sora...
Purpose: To clarify the effects of cyclin E1 suppression on antitumor efficacy of sorafenib in hepat...
Xudong Gao,1,2 Hebing Chen,1 Xin Huang,1 Hao Li,1 Zhen Liu,1 Xiaochen Bo1 1Beijing Institute of Rad...
Introduction:Targeting signal transducer and activator of transcription 3 (STAT3), a transcription f...
Sorafenib inhibits intracellular signaling pathways addition to inhibiting AKT and receptor tyrosine...
none4noHepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldw...
Background: Traditional systemic chemotherapy does not provide survival benefits in patients with he...
The present study investigated the effect of YC-1, a novel anti-cancer agent, on the chemo-sensitivi...
Background& Aims: Recently, we reported that sorafenib sensitizes hepatocellular carcinoma (HCC) cel...
Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer with incidence increasing w...
Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after i...
YC-1 has recently been demonstrated to have potent anti-invasion and anti-metastatic activity in sev...
PURPOSE: Recombinant tumor necrosis factor-related apoptosis -inducing ligand (TRAIL) is a promising...
Hypoxia-inducible factor-1alpha (HIF-1alpha) seems central to tumor growth and progression because i...
BACKGROUND AND PURPOSE YC-1 exhibits potent anticancer activity via numerous actions in many cancer...
The role of a YAP-IGF-1R signaling loop in HCC resistance to sorafenib remains unknown. Method: Sora...
Purpose: To clarify the effects of cyclin E1 suppression on antitumor efficacy of sorafenib in hepat...
Xudong Gao,1,2 Hebing Chen,1 Xin Huang,1 Hao Li,1 Zhen Liu,1 Xiaochen Bo1 1Beijing Institute of Rad...
Introduction:Targeting signal transducer and activator of transcription 3 (STAT3), a transcription f...
Sorafenib inhibits intracellular signaling pathways addition to inhibiting AKT and receptor tyrosine...
none4noHepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldw...